Abstract

This chapter presents a series of case studies and multiple choice questions and answers on the role of PET scans in lymphomas. It commences with a discourse on the evidence of extranodal disease leading to stage IV disease. One case study explains how one can recommend proceeding based on the PET-CT findings. Peripheral T-cell lymphomas (PTCLs) account for 10-15 percent of newly diagnosed non-Hodgkin's lymphoma. Changes in PET scans following therapy reflect the impact of the drugs on the cancer, and individual anticancer drugs such as rituximab do not, by themselves, affect the outcome of a PET scan. PET scans have been proposed as a way to determine if a residual mediastinal mass in a patient who has been treated for Hodgkin lymphoma represents active disease. The chapter further talks about relapse on subsequent follow-up.

Original languageEnglish (US)
Title of host publicationCancer Consult
Subtitle of host publicationExpertise for Clinical Practice
PublisherWiley-Blackwell
Pages389-397
Number of pages9
ISBN (Electronic)9781118589199
ISBN (Print)9781118589212
DOIs
StatePublished - Jun 20 2014

Fingerprint

Positron-Emission Tomography
Lymphoma
Peripheral T-Cell Lymphoma
Hodgkin Disease
Pharmaceutical Preparations
Non-Hodgkin's Lymphoma
Recurrence
Neoplasms
Therapeutics

Keywords

  • Hodgkin lymphoma
  • Lymphomas
  • PET scans
  • PET-CT findings
  • Peripheral T-cell lymphomas (PTCLs)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lunning, M. A., & Armitage, J. O. (2014). Role of PET Scan in Lymphomas. In Cancer Consult: Expertise for Clinical Practice (pp. 389-397). Wiley-Blackwell. https://doi.org/10.1002/9781118589199.ch61

Role of PET Scan in Lymphomas. / Lunning, Matthew A; Armitage, James Olen.

Cancer Consult: Expertise for Clinical Practice. Wiley-Blackwell, 2014. p. 389-397.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lunning, MA & Armitage, JO 2014, Role of PET Scan in Lymphomas. in Cancer Consult: Expertise for Clinical Practice. Wiley-Blackwell, pp. 389-397. https://doi.org/10.1002/9781118589199.ch61
Lunning MA, Armitage JO. Role of PET Scan in Lymphomas. In Cancer Consult: Expertise for Clinical Practice. Wiley-Blackwell. 2014. p. 389-397 https://doi.org/10.1002/9781118589199.ch61
Lunning, Matthew A ; Armitage, James Olen. / Role of PET Scan in Lymphomas. Cancer Consult: Expertise for Clinical Practice. Wiley-Blackwell, 2014. pp. 389-397
@inbook{57349e0e65204766a5325f406f2052f1,
title = "Role of PET Scan in Lymphomas",
abstract = "This chapter presents a series of case studies and multiple choice questions and answers on the role of PET scans in lymphomas. It commences with a discourse on the evidence of extranodal disease leading to stage IV disease. One case study explains how one can recommend proceeding based on the PET-CT findings. Peripheral T-cell lymphomas (PTCLs) account for 10-15 percent of newly diagnosed non-Hodgkin's lymphoma. Changes in PET scans following therapy reflect the impact of the drugs on the cancer, and individual anticancer drugs such as rituximab do not, by themselves, affect the outcome of a PET scan. PET scans have been proposed as a way to determine if a residual mediastinal mass in a patient who has been treated for Hodgkin lymphoma represents active disease. The chapter further talks about relapse on subsequent follow-up.",
keywords = "Hodgkin lymphoma, Lymphomas, PET scans, PET-CT findings, Peripheral T-cell lymphomas (PTCLs)",
author = "Lunning, {Matthew A} and Armitage, {James Olen}",
year = "2014",
month = "6",
day = "20",
doi = "10.1002/9781118589199.ch61",
language = "English (US)",
isbn = "9781118589212",
pages = "389--397",
booktitle = "Cancer Consult",
publisher = "Wiley-Blackwell",
address = "United States",

}

TY - CHAP

T1 - Role of PET Scan in Lymphomas

AU - Lunning, Matthew A

AU - Armitage, James Olen

PY - 2014/6/20

Y1 - 2014/6/20

N2 - This chapter presents a series of case studies and multiple choice questions and answers on the role of PET scans in lymphomas. It commences with a discourse on the evidence of extranodal disease leading to stage IV disease. One case study explains how one can recommend proceeding based on the PET-CT findings. Peripheral T-cell lymphomas (PTCLs) account for 10-15 percent of newly diagnosed non-Hodgkin's lymphoma. Changes in PET scans following therapy reflect the impact of the drugs on the cancer, and individual anticancer drugs such as rituximab do not, by themselves, affect the outcome of a PET scan. PET scans have been proposed as a way to determine if a residual mediastinal mass in a patient who has been treated for Hodgkin lymphoma represents active disease. The chapter further talks about relapse on subsequent follow-up.

AB - This chapter presents a series of case studies and multiple choice questions and answers on the role of PET scans in lymphomas. It commences with a discourse on the evidence of extranodal disease leading to stage IV disease. One case study explains how one can recommend proceeding based on the PET-CT findings. Peripheral T-cell lymphomas (PTCLs) account for 10-15 percent of newly diagnosed non-Hodgkin's lymphoma. Changes in PET scans following therapy reflect the impact of the drugs on the cancer, and individual anticancer drugs such as rituximab do not, by themselves, affect the outcome of a PET scan. PET scans have been proposed as a way to determine if a residual mediastinal mass in a patient who has been treated for Hodgkin lymphoma represents active disease. The chapter further talks about relapse on subsequent follow-up.

KW - Hodgkin lymphoma

KW - Lymphomas

KW - PET scans

KW - PET-CT findings

KW - Peripheral T-cell lymphomas (PTCLs)

UR - http://www.scopus.com/inward/record.url?scp=84946414461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946414461&partnerID=8YFLogxK

U2 - 10.1002/9781118589199.ch61

DO - 10.1002/9781118589199.ch61

M3 - Chapter

AN - SCOPUS:84946414461

SN - 9781118589212

SP - 389

EP - 397

BT - Cancer Consult

PB - Wiley-Blackwell

ER -